Structures by: Griesser U. J.
Total: 118
Phenobarbital dioxane hemisolvate
C12H12N2O3,0.5(C4H8O2)
The journal of physical chemistry. B (2014) 118, 12 3267-3280
a=6.86417(15)Å b=11.9645(2)Å c=16.6842(4)Å
α=90° β=98.071(2)° γ=90°
Phenobarbital dichloromethane monosolvate
C12H12N2O3,CH2Cl2
The journal of physical chemistry. B (2014) 118, 12 3267-3280
a=8.6980(5)Å b=11.9681(6)Å c=14.2590(7)Å
α=90.00° β=97.470(5)° γ=90.00°
Phenobarbital nitromethane monosolvate
C12H12N2O3,CH3NO2
The journal of physical chemistry. B (2014) 118, 12 3267-3280
a=10.2543(14)Å b=10.4086(15)Å c=13.7090(19)Å
α=98.774(11)° β=96.171(11)° γ=98.962(3)°
Phenobarbital dioxane monosolvate
C12H12N2O3,C4H8O2
The journal of physical chemistry. B (2014) 118, 12 3267-3280
a=10.6052(3)Å b=10.5502(2)Å c=14.6810(4)Å
α=90° β=92.028(2)° γ=90°
Phenobarbital dioxane monosolvate
C12H12N2O3,C4H8O2
The journal of physical chemistry. B (2014) 118, 12 3267-3280
a=17.639(2)Å b=10.4165(8)Å c=18.374(2)Å
α=90.00° β=108.281(9)° γ=90.00°
Phenobarbital acetonitrile monosolvate
C12H12N2O3,C2H3N
The journal of physical chemistry. B (2014) 118, 12 3267-3280
a=10.1600(7)Å b=10.3036(11)Å c=14.0553(12)Å
α=99.674(8)° β=96.774(6)° γ=97.811(7)°
Codeine Monohydrate
C18H21NO3,H2O
Molecular pharmaceutics (2014) 11, 9 3145-3163
a=10.3994(2)Å b=12.5671(2)Å c=12.0640(2)Å
α=90° β=90° γ=90°
Codeine Hydrochloride Dihydrate
C18H22NO31,Cl1,2(H2O)
Molecular pharmaceutics (2014) 11, 9 3145-3163
a=6.7621(5)Å b=12.9315(9)Å c=20.3080(14)Å
α=90° β=90° γ=90°
Codeine Hydrochloride Anhydrate I
C18H22NO3,Cl
Molecular pharmaceutics (2014) 11, 9 3145-3163
a=7.14435(17)Å b=13.2304(3)Å c=16.5408(4)Å
α=90° β=90° γ=90°
Ethylmorphine Monohydrate
C19H23NO3,H2O
Molecular pharmaceutics (2014) 11, 9 3145-3163
a=7.08246(18)Å b=13.1493(3)Å c=18.0581(5)Å
α=90° β=90° γ=90°
Ethylmorphine Hydrochloride Dihydrate
C19H24NO3,Cl,2(H2O)
Molecular pharmaceutics (2014) 11, 9 3145-3163
a=6.8715(2)Å b=13.3924(4)Å c=20.4176(5)Å
α=90° β=90° γ=90°
C14H13N3O
C14H13N3O
CrystEngComm (2015) 17, 28 5143
a=13.488(2)Å b=9.6611(15)Å c=9.3604(13)Å
α=90° β=90.183(5)° γ=90°
C14H13N3O
C14H13N3O
CrystEngComm (2015) 17, 28 5143
a=25.8998(13)Å b=5.5463(3)Å c=8.3187(4)Å
α=90° β=95.876(4)° γ=90°
C14H13N3O
C14H13N3O
CrystEngComm (2015) 17, 28 5143
a=10.2114(2)Å b=30.3315(7)Å c=8.2353(2)Å
α=90° β=110.1930(10)° γ=90°
C14H13N3O
C14H13N3O
CrystEngComm (2015) 17, 28 5143
a=6.3542(4)Å b=7.6624(6)Å c=49.231(3)Å
α=90° β=90° γ=90°
Isonicotinic acid-(1-phenyl-ethylidenehydrazide)
C14H13N3O
CrystEngComm (2015) 17, 28 5143
a=10.6217(16)Å b=14.442(2)Å c=8.2589(12)Å
α=90° β=109.623(5)° γ=90°
C14H13N3O
C14H13N3O
CrystEngComm (2015) 17, 28 5143
a=9.7360(6)Å b=9.8752(6)Å c=26.1543(16)Å
α=92.856(4)° β=100.295(4)° γ=91.291(4)°
Carbamazepine dihydrate
C15H12N2O,2(H2O)
Organic Process Research & Development (2005) 9, 6 902
a=10.066(2)Å b=28.719(5)Å c=4.831(1)Å
α=90.00° β=103.45(1)° γ=90.00°
1,3,5-trihydroxybenzene dihydrate
C6H6O3,2(H2O)
The journal of physical chemistry. B (2012) 116, 13 3961-3972
a=6.6209(17)Å b=13.5606(25)Å c=8.0462(15)Å
α=90° β=90° γ=90°
C7H11N2OS,Br
C7H11N2OS,Br
CrystEngComm (2020)
a=11.2359(2)Å b=14.9020(2)Å c=12.3361(3)Å
α=90° β=111.2210(10)° γ=90°
C7H11N2OS,Cl
C7H11N2OS,Cl
CrystEngComm (2020)
a=11.1116(2)Å b=14.6502(3)Å c=12.1138(4)Å
α=90° β=111.270(2)° γ=90°
C5H9N4OS,Br
C5H9N4OS,Br
CrystEngComm (2020)
a=5.8057(3)Å b=19.4234(11)Å c=8.3009(5)Å
α=90° β=102.153(5)° γ=90°
C7H11N2OS,Cl
C7H11N2OS,Cl
CrystEngComm (2020)
a=17.1960(8)Å b=8.4197(5)Å c=6.6408(3)Å
α=90° β=95.281(4)° γ=90°
Aprepitant, form II
C23H21F7N4O3
New Journal of Chemistry (2008) 32, 10 1677
a=7.7768(16)Å b=7.4072(11)Å c=21.297(5)Å
α=90° β=92.861(17)° γ=90°
Aprepitant, form I
C23H21F7N4O3
New Journal of Chemistry (2008) 32, 10 1677
a=7.421(4)Å b=7.710(4)Å c=42.200(2)Å
α=90° β=90° γ=90°
3-(3-methylimidazolium-1-yl)propanoate dihydrate
C7H10N2O2,2(H2O)
CrystEngComm (2018) 20, 48 7826
a=7.3825(4)Å b=8.4170(4)Å c=8.8371(4)Å
α=113.2550(10)° β=105.1800(10)° γ=95.990(2)°
3-(3-methylimidazolium-1-yl)propanoate
C7H10N2O2
CrystEngComm (2018) 20, 48 7826
a=6.6643(4)Å b=8.7065(5)Å c=12.8000(8)Å
α=90° β=90° γ=90°
3-(3-methylimidazolium-1-yl)propanoate monohydrate
C7H10N2O2,H2O
CrystEngComm (2018) 20, 48 7826
a=7.7258(7)Å b=12.6758(12)Å c=8.8421(9)Å
α=90° β=105.550(10)° γ=90°
1 (2 carboxyethyl)-3-methylimidazolium chloride
C7H11N2O2,Cl
CrystEngComm (2018) 20, 48 7826
a=20.1911(9)Å b=7.9146(3)Å c=22.5627(11)Å
α=90° β=92.268(2)° γ=90°
Dapsone nitromethane hemisolvate
2(C12H12N2O2S),CH3NO2
CrystEngComm (2019) 21, 36 5533
a=8.4167(2)Å b=16.3415(3)Å c=19.1383(4)Å
α=90° β=95.832(2)° γ=90°
Dapsone acetonitrile hemisolvate
2(C12H12N2O2S),C2H3N
CrystEngComm (2019) 21, 36 5533
a=8.5132(2)Å b=16.1830(3)Å c=18.9865(4)Å
α=90° β=97.818(2)° γ=90°
Cinacalcet HCl acetic acid solvate
C24H27ClF3NO2
CrystEngComm (2008) 10, 11 1617
a=7.5434(8)Å b=18.575(2)Å c=16.7756(19)Å
α=90° β=90° γ=90°
C8H16N,Cl
C8H16N,Cl
CrystEngComm (2008) 10, 6 748
a=6.4857(10)Å b=12.005(3)Å c=12.526(2)Å
α=90.00° β=102.746(13)° γ=90.00°
C8H14N,Cl
C8H14N,Cl
CrystEngComm (2008) 10, 6 748
a=8.4849(14)Å b=8.1271(16)Å c=13.501(2)Å
α=90.00° β=100.408(13)° γ=90.00°
Pentobarbital, nembutal
C11H18N2O3
CrystEngComm (2012) 14, 7 2494
a=11.7361(6)Å b=11.1568(9)Å c=10.1886(6)Å
α=90.00° β=110.205(6)° γ=90.00°
Pentobarbital, nembutal
C11H18N2O3
CrystEngComm (2012) 14, 7 2494
a=16.7545(15)Å b=9.8660(8)Å c=7.1799(5)Å
α=90.00° β=90.00° γ=90.00°
Co-crystal phenobarbital + nembutal
(C12H12N2O3),(C11H18N2O3)
CrystEngComm (2012) 14, 7 2494
a=12.6733(11)Å b=20.6887(19)Å c=10.2529(7)Å
α=90.00° β=118.458(9)° γ=90.00°
Pentobarbital, nembutal
C11H18N2O3
CrystEngComm (2012) 14, 7 2494
a=14.5136(10)Å b=6.8344(3)Å c=12.4979(6)Å
α=90.00° β=104.762(6)° γ=90.00°
Nembutal, pentobarbital
C11H18N2O3
CrystEngComm (2012) 14, 7 2494
a=11.8675(10)Å b=21.824(3)Å c=10.2201(9)Å
α=90.00° β=110.476(9)° γ=90.00°
5,5-dichlorobarbituric acid
C4H2Cl2N2O3
CrystEngComm (2011) 13, 17 5502
a=11.3096(3)Å b=12.9226(4)Å c=29.1608(8)Å
α=90.00° β=90.00° γ=90.00°
5,5-dibromorobarbituric acid
C4H2Br2N2O3
CrystEngComm (2011) 13, 17 5502
a=11.4204(2)Å b=12.9897(3)Å c=30.0304(8)Å
α=90.00° β=90.00° γ=90.00°
5,5-dibromorobarbituric acid
C4H2Br2N2O3
CrystEngComm (2011) 13, 17 5502
a=17.5105(12)Å b=6.6869(3)Å c=13.6714(9)Å
α=90.00° β=110.493(8)° γ=90.00°
5,5-dichlorobarbituric acid
C4H2Cl2N2O3
CrystEngComm (2011) 13, 17 5502
a=11.5440(3)Å b=11.5528(3)Å c=20.0656(5)Å
α=90.00° β=100.481(3)° γ=90.00°
4-aminoquinaldine monohydrate
C10H10N2,H2O
CrystEngComm (2016) 18, 22 4053
a=4.7832(5)Å b=12.0775(4)Å c=16.3371(5)Å
α=90.00000° β=92.226(3)° γ=90.00000°
C8H18N,Cl
C8H18N,Cl
CrystEngComm (2008) 10, 6 748
a=10.0354(11)Å b=13.254(2)Å c=14.6231(16)Å
α=90.00° β=90.00° γ=90.00°
Propallylonal, noctal, nostal, quietal, ibomal
C10H13BrN2O3
CrystEngComm (2011) 13, 17 5502
a=8.0916(3)Å b=11.3472(5)Å c=13.2670(4)Å
α=90.00° β=105.773(2)° γ=90.00°
Cytosine/5-flucytosine solid solution I
C4H4.359F0.641N3O1
CrystEngComm (2017)
a=4.00808(9)Å b=9.43931(11)Å c=13.0306(2)Å
α=90° β=91.179(2)° γ=90°
Cytosine/5-flucytosine solid solution I
C4H4.393F0.607N3O1
CrystEngComm (2017)
a=6.67372(5)Å b=6.67372(5)Å c=23.6290(3)Å
α=90° β=90° γ=90°
C12H10F13N2S,I
C12H10F13N2S,I
Green Chem. (2017)
a=6.4269(3)Å b=8.9443(5)Å c=16.3677(9)Å
α=85.570(5)° β=81.795(4)° γ=86.766(5)°
C12H10F13N2S1,Cl1
C12H10F13N2S1,Cl1
Green Chem. (2017)
a=6.3654(4)Å b=9.2363(5)Å c=16.0361(12)Å
α=75.231(5)° β=83.709(5)° γ=76.855(5)°
2(C12H10F13N2S1),SiF62
2(C12H10F13N2S1),SiF62
Green Chem. (2017)
a=18.463(5)Å b=8.901(3)Å c=11.595(3)Å
α=90° β=102.185(9)° γ=90°
C20H13F26IN2S
C20H13F26IN2S
Green Chem. (2017)
a=5.8881(3)Å b=10.2741(7)Å c=25.4810(10)Å
α=89.763(4)° β=87.419(4)° γ=77.726(3)°
C12H10F13N2S1,C8F17I,I1
C12H10F13N2S1,C8F17I,I1
Green Chem. (2017)
a=6.4954(5)Å b=9.2039(8)Å c=27.9195(19)Å
α=94.848(6)° β=91.767(6)° γ=95.367(7)°
C15H15F13N2O3S2
C15H15F13N2O3S2
Green Chem. (2017)
a=8.6657(2)Å b=10.1187(4)Å c=48.601(2)Å
α=90° β=90° γ=90°
4-aminoquinaldine form I
C10H10N2
CrystEngComm / RSC (2015) 17, 12 2504-2516
a=5.2162(4)Å b=12.3693(9)Å c=13.1192(9)Å
α=90° β=99.065(3)° γ=90°
4-aminoquinaldine form II
C10H10N2,C0.08Cl0.33
CrystEngComm / RSC (2015) 17, 12 2504-2516
a=28.4074(8)Å b=28.4074(8)Å c=11.9126(5)Å
α=90° β=90° γ=120°
(2<i>S</i>,3<i>R</i>,4<i>R</i>,5<i>S</i>,6<i>R</i>)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylsulfanyl)tetrahydro-2<i>H</i>-pyran-3,4,5-triol
C21H25ClO5S
Acta Crystallographica Section C (2017) 73, 9
a=5.3945(4)Å b=9.1577(5)Å c=43.475(4)Å
α=90° β=90° γ=90°
(2<i>S</i>,3<i>R</i>,4<i>R</i>,5<i>S</i>,6<i>R</i>)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylsulfanyl)tetrahydro-2<i>H</i>-pyran-3,4,5-triol monohydrate
C21H25ClO5S,H2O
Acta Crystallographica Section C (2017) 73, 9
a=4.4659(3)Å b=9.8994(8)Å c=48.073(5)Å
α=90° β=90° γ=90°
Febuxostat ethanol monosolvate
C16H16N2O3S,C2H6O
Acta Crystallographica Section E (2020) 76, 6 816-819
a=4.7274(2)Å b=17.7820(5)Å c=10.7340(4)Å
α=90° β=98.994(4)° γ=90°
Methohexital
C14H18N2O3
Acta Crystallographica Section E (2015) 71, 2 206-209
a=7.7502(6)Å b=7.9792(5)Å c=12.6881(10)Å
α=93.713(6)° β=96.226(6)° γ=113.314(7)°
Naloxegol hydrogen oxalate
C34H54NO11,C2HO4
Acta Crystallographica Section E (2018) 74, 4 474-477
a=10.35810(10)Å b=13.40390(10)Å c=26.1689(2)Å
α=90° β=90° γ=90°
5-Hydroxy-5-propylbarbituric acid
C7H10N2O4
Acta Crystallographica Section E (2015) 71, 11 1311-1314
a=10.7862(8)Å b=6.7093(5)Å c=11.7365(6)Å
α=90° β=98.632(6)° γ=90°
Buthalital (Bayinal, Baytinal, Thialbutal, Transithal, Ulbreval)
C11H16N2O2S
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 12 1908-1912
a=8.7271(6)Å b=11.6521(4)Å c=12.5400(8)Å
α=90° β=96.539(2)° γ=90°
Methitural (Neraval, Thiogenal)
C12H20N2O2S2
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 12 1908-1912
a=15.1873(2)Å b=9.09200(10)Å c=20.8684(3)Å
α=90° β=96.0830(10)° γ=90°
Alogliptin
C18H21N5O2
Acta Crystallographica Section C (2013) 69, 6 674-678
a=8.4528(5)Å b=8.5689(5)Å c=12.4424(7)Å
α=87.840(5)° β=72.284(5)° γ=87.368(8)°
Alogliptin benzoate
C18H22N5O2,C7H5O2
Acta Crystallographica Section C (2013) 69, 6 674-678
a=8.0666(2)Å b=9.8727(2)Å c=28.4593(6)Å
α=90° β=90° γ=90°
5-Cyclohexyl-5-ethylbarbituric acid form I
C12H18N2O3
Acta Crystallographica Section C (2015) 71, 3
a=17.9322(4)Å b=10.4961(3)Å c=13.2006(4)Å
α=90° β=95.896(2)° γ=90°
5-Cyclohexyl-5-ethylbarbituric acid form II
C12H18N2O3
Acta Crystallographica Section C (2015) 71, 3
a=12.5071(7)Å b=21.0741(9)Å c=10.3310(5)Å
α=90° β=116.989(5)° γ=90°
Sulfasymazine
C13H17N5O2S
Acta Crystallographica Section C (2008) 64, 6 o309-o312
a=9.3257(2)Å b=16.7918(4)Å c=9.8600(2)Å
α=90.00° β=110.6930(10)° γ=90.00°
Sulfatriazine
C11H13N5O4S
Acta Crystallographica Section C (2008) 64, 6 o309-o312
a=8.1566(3)Å b=8.6577(4)Å c=10.5410(4)Å
α=97.180(3)° β=103.374(2)° γ=109.255(2)°
Narconumal, Enallylpropymal
C11H16N2O3
Acta Crystallographica Section C (2010) 66, 1 o55-o58
a=6.4160(7)Å b=7.9559(8)Å c=11.9569(12)Å
α=77.574(7)° β=80.837(7)° γ=75.518(6)°
1,5-di(but-2-enyl)-5-ethylbarbituric acid
C14H20N2O3
Acta Crystallographica Section C (2010) 66, 1 o55-o58
a=10.2825(11)Å b=13.2972(16)Å c=10.3959(10)Å
α=90° β=92.999(7)° γ=90°
Telaprevir
C36H53N7O6
Acta Crystallographica Section C (2013) 69, 2 179-182
a=10.4235(2)Å b=19.1651(2)Å c=37.2907(4)Å
α=90.00° β=90.00° γ=90.00°
Codeine hydrogen dihydrogen phosphate hemihydrate
C18H22NO3,H2O4P,0.5H2O
Acta Crystallographica Section C (2009) 65, 8 o419-o422
a=6.9113(2)Å b=33.4470(9)Å c=8.0716(2)Å
α=90.00° β=99.778(3)° γ=90.00°
Acemetacin monohydrate
C21H18ClNO6,H2O
Acta Crystallographica Section C (2007) 63, 8 o451-o453
a=7.7257(3)Å b=10.2208(3)Å c=13.4225(4)Å
α=96.879(2)° β=96.354(2)° γ=107.158(2)°
Butobarbital
C10H16N2O3
Acta Crystallographica Section C (2007) 63, 12 o751-o753
a=6.85340(10)Å b=29.6631(7)Å c=22.2107(5)Å
α=90.00° β=94.4080(10)° γ=90.00°
Plumeridoid C
C15H18O7
Acta Crystallographica Section C (2011) 67, 10 o409-o412
a=9.6736(2)Å b=7.62030(10)Å c=10.6303(2)Å
α=90.00° β=107.142(2)° γ=90.00°
Eldoral
C11H17N3O3
Acta Crystallographica Section C (2012) 68, 2 o65-o70
a=7.8761(2)Å b=12.7102(4)Å c=11.9438(3)Å
α=90.00° β=98.189(3)° γ=90.00°
Eldoral
C11H17N3O3
Acta Crystallographica Section C (2012) 68, 2 o65-o70
a=11.9311(3)Å b=15.9858(4)Å c=13.0768(3)Å
α=90.00° β=106.7990(10)° γ=90.00°
Diethylammonium 5-ethyl-2,4,6-trioxo-5-(piperidin-1-yl)-1,3-diazinan-1-ide
C4H12N,C11H16N3O3
Acta Crystallographica Section C (2012) 68, 2 o65-o70
a=11.8270(3)Å b=16.1719(4)Å c=18.6774(5)Å
α=90.00° β=90.00° γ=90.00°
Diphenylmethanesulfonamide
C13H14N2O4S2
Acta Crystallographica Section E (2010) 66, 7 o1619
a=10.8251(5)Å b=5.0791(3)Å c=12.6912(5)Å
α=90° β=90.931(3)° γ=90°
Polythiazide
C11H13ClF3N3O4S3
Acta Crystallographica Section E (2010) 66, 7 o1663-o1664
a=14.6659(7)Å b=9.5498(6)Å c=13.6720(7)Å
α=90.00° β=116.149(3)° γ=90.00°
Butallylonal 1,4-dioxane hemisolvate
C11H15BrN2O3,0.5(C4H8O2)
Acta Crystallographica Section E (2010) 66, 10 o2688
a=10.494(2)Å b=6.7679(8)Å c=21.864(3)Å
α=90.00° β=97.294(15)° γ=90.00°
5,5-dihydroxybarbituric acid 1,4-dioxane hemisolvate
C4H4N2O5,0.5(C4H8O2)
Acta Crystallographica Section E (2010) 66, 5 o1219
a=6.0232(3)Å b=8.3954(4)Å c=8.6858(5)Å
α=106.007(4)° β=94.459(3)° γ=110.126(3)°
Proseptazine
C13H14N2O2S
Acta Crystallographica Section E (2011) 67, 6 o1551-o1552
a=7.84260(10)Å b=10.5549(11)Å c=14.6694(3)Å
α=90.00° β=90.00° γ=90.00°
Morphine
C17H19NO3
Acta Crystallographica Section E (2013) 69, 1 o2
a=7.6989(10)Å b=12.737(4)Å c=13.740(4)Å
α=90.00° β=90.00° γ=90.00°
Gliquidone
C27H33N3O6S
Acta Crystallographica Section E (2011) 67, 6 o1343
a=19.1494(4)Å b=10.7253(3)Å c=13.8024(2)Å
α=90.00° β=106.6910(10)° γ=90.00°
5,5-dichlorobarbituric acid
C4H2Cl2N2O3
Acta Crystallographica Section E (2012) 68, 1 o235-o236
a=13.8883(3)Å b=13.8883(3)Å c=6.9126(2)Å
α=90.00° β=90.00° γ=90.00°
Morphine hydrochloride anhydrate
C17H20NO3,Cl
Acta Crystallographica Section E (2012) 68, 12 o3358-o3359
a=7.3504(2)Å b=12.8524(5)Å c=16.0372(5)Å
α=90.00° β=90.00° γ=90.00°
Creatine anhydrate B
C4H9N3O2
Crystal Growth & Design (2014) 14, 10 4895
a=5.4857(3)Å b=11.4417(4)Å c=9.9624(5)Å
α=90.00000° β=98.663(5)° γ=90.00000°
Creatine anhydrate form C
C4H9N3O2
Crystal Growth & Design (2014) 14, 10 4895
a=11.9504(3)Å b=5.3453(2)Å c=9.5314(3)Å
α=90.00000° β=90.00000° γ=90.00000°
C18H26BF4Fe
C18H26BF4Fe
Journal of the American Chemical Society (2005) 127, 6795-6801
a=13.6067(9)Å b=8.1374(4)Å c=17.5031(9)Å
α=90.00° β=109.835(3)° γ=90.00°
α-indomethacin
C19H16ClNO4
Journal of the American Chemical Society (2002) 124, 50 15012-15019
a=5.4616(16)Å b=25.310(9)Å c=18.152(7)Å
α=90.00° β=94.38(3)° γ=90.00°
Beta resoryclic acid form I
C7H6O4
Crystal growth & design (2011) 11, 1 210-220
a=23.1978(4)Å b=5.5469(1)Å c=5.1980(1)Å
α=90° β=92.215(1)° γ=90°
Beta resoryclic acid hemihydrate
2(C7H6O4),H2O
Crystal growth & design (2011) 11, 1 210-220
a=7.0270(4)Å b=9.5449(4)Å c=11.1763(5)Å
α=96.684(4)° β=104.319(5)° γ=98.903(4)°
Beta resoryclic DMSO hemisolvate
2(C7H6O4),C2H6OS
Crystal growth & design (2011) 11, 1 210-220
a=6.39832(12)Å b=11.7099(3)Å c=23.2362(5)Å
α=90° β=90° γ=90°
Beta resoryclate pyridinium salt
C7H5O4,C5H6N
Crystal growth & design (2011) 11, 1 210-220
a=11.7363(4)Å b=8.5691(2)Å c=11.8310(4)Å
α=90° β=115.973(5)° γ=90°
4-amino-1,2,4-triazole hydrochloride
C2H5ClN4
Crystal Growth & Design (2006) 6, 2 404
a=7.1584(14)Å b=8.1640(16)Å c=9.3954(19)Å
α=90.00° β=102.97(3)° γ=90.00°
1-aminoimidazole hydrochloride
C3H6ClN3
Crystal Growth & Design (2006) 6, 2 404
a=9.3559(19)Å b=4.9432(10)Å c=12.182(2)Å
α=90.00° β=97.76(3)° γ=90.00°